

May 17, 2019

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
--	--

Dear Sirs,

Re: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sub: USFDA classifies the inspection of Aurobindo's API/ Intermediates facilities of Unit I, IX and XI as OAI

This is to inform that the Company has received letters from the USFDA classifying the inspections concluded at our API facilities of Unit I and XI and intermediates facility of unit IX in February 2019 as Official Action Indicated (OAI).

The Company has already submitted its initial response to USFDA. The Company is sending further updates on the committed corrective actions.

The Company is confident that these OAI classifications will not have an impact on disruption of supplies or the revenue from operations of these facilities.

Please take the information on record.

Thanking you,

Yours faithfully,
For AUROBINDO PHARMA LIMITED


B. Adi Reddy
Company Secretary

